Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Subscribe To Our Newsletter & Stay Updated
